IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.392
AS - Asia 12.126
EU - Europa 10.747
SA - Sud America 2.404
AF - Africa 1.025
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 20
Totale 52.744
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.323
SG - Singapore 6.858
CN - Cina 3.503
IE - Irlanda 2.647
IT - Italia 2.594
UA - Ucraina 2.397
BR - Brasile 2.055
RU - Federazione Russa 1.282
CA - Canada 912
CI - Costa d'Avorio 679
VN - Vietnam 563
SE - Svezia 333
DE - Germania 315
GB - Regno Unito 307
IN - India 287
KR - Corea 220
SN - Senegal 139
AR - Argentina 138
FI - Finlandia 118
FR - Francia 112
NL - Olanda 108
MX - Messico 104
PL - Polonia 103
CH - Svizzera 88
JP - Giappone 86
BD - Bangladesh 85
UZ - Uzbekistan 82
ZA - Sudafrica 76
EC - Ecuador 66
AT - Austria 63
TR - Turchia 60
IQ - Iraq 55
ES - Italia 53
CZ - Repubblica Ceca 50
HK - Hong Kong 48
BE - Belgio 47
GR - Grecia 44
ID - Indonesia 37
LB - Libano 36
CO - Colombia 35
MA - Marocco 35
VE - Venezuela 28
PK - Pakistan 27
IR - Iran 26
AU - Australia 21
CL - Cile 21
IL - Israele 20
PY - Paraguay 20
BJ - Benin 18
EU - Europa 18
SA - Arabia Saudita 18
JO - Giordania 17
EG - Egitto 16
PE - Perù 16
AE - Emirati Arabi Uniti 15
KE - Kenya 15
LT - Lituania 14
TN - Tunisia 14
BG - Bulgaria 13
BO - Bolivia 13
DO - Repubblica Dominicana 12
NG - Nigeria 12
RS - Serbia 12
AZ - Azerbaigian 11
KZ - Kazakistan 11
DZ - Algeria 10
NO - Norvegia 9
RO - Romania 9
UY - Uruguay 9
CR - Costa Rica 7
KW - Kuwait 7
MY - Malesia 7
NZ - Nuova Zelanda 7
PS - Palestinian Territory 7
AL - Albania 6
JM - Giamaica 6
NP - Nepal 6
OM - Oman 6
PA - Panama 6
TH - Thailandia 6
BH - Bahrain 5
PH - Filippine 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
BB - Barbados 4
HN - Honduras 3
HU - Ungheria 3
LU - Lussemburgo 3
PT - Portogallo 3
AM - Armenia 2
AO - Angola 2
BF - Burkina Faso 2
DK - Danimarca 2
EE - Estonia 2
GD - Grenada 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NI - Nicaragua 2
SR - Suriname 2
SV - El Salvador 2
Totale 52.717
Salva come PNG Salva come JPEG
Città #
Dallas 5.120
Singapore 3.484
Santa Clara 2.901
Jacksonville 2.636
Dublin 2.628
Chandler 2.134
Boardman 1.117
Chicago 955
Catania 899
Ashburn 869
Nanjing 751
Cambridge 720
Andover 716
Lawrence 715
Abidjan 677
Toronto 651
Houston 510
Hefei 501
Moscow 442
Des Moines 423
Los Angeles 421
Beijing 394
San Mateo 386
Nanchang 262
Wilmington 261
Civitanova Marche 229
Seoul 220
Saint Petersburg 182
Shenyang 180
São Paulo 177
Hebei 176
Ho Chi Minh City 174
Buffalo 166
Jiaxing 148
Ottawa 148
New York 144
Dakar 138
Changsha 134
Florence 133
Tianjin 110
Hanoi 105
Rome 102
Grafing 96
Council Bluffs 94
Kochi 92
Dong Ket 87
Milan 85
Palermo 74
Tokyo 74
Brooklyn 71
Munich 71
Seattle 67
Warsaw 65
Montreal 62
Rio de Janeiro 59
Washington 58
Stockholm 53
Boston 51
Johannesburg 51
The Dalles 51
San Francisco 49
Belo Horizonte 48
Columbus 46
Hangzhou 45
Hong Kong 45
Phoenix 44
Redondo Beach 44
Brussels 42
Turku 42
Chennai 41
Poplar 41
Denver 40
Den Haag 39
Helsinki 38
Lappeenranta 37
Norwalk 37
Kunming 35
Mexico City 33
Atlanta 32
Falls Church 32
London 32
Pune 32
Tashkent 32
Mumbai 31
Orem 30
Jinan 29
Porto Alegre 29
Amsterdam 28
Bremen 28
Ankara 27
Brasília 27
Curitiba 27
Guangzhou 25
Campinas 24
Bari 22
Brno 22
Guayaquil 22
Messina 22
Quito 22
Ann Arbor 20
Totale 35.841
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 254
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 248
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 190
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 183
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 183
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 176
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 160
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 158
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 154
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 151
Il Rasario. Semeiotica medica 149
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 143
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 142
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 138
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 137
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 137
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 134
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 133
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 133
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 133
Hedgehog signaling pathways in multiple myeloma 127
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 126
A snapshot of asparaginase-induced liver insufficiency. 126
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 126
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 125
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 125
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 124
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 123
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 123
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 122
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 122
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 122
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 121
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 120
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 120
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol 119
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 119
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 118
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 118
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 117
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 117
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 117
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 117
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 117
Acute pre-hepatic portal thrombosis: diagnosis and therapy 116
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 116
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 115
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 115
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 114
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents 114
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 113
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 113
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 113
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 113
Terapia del mieloma multiplo 112
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 112
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 112
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 111
A case of high-risk AML in a patient with advanced systemic mastocytosis 111
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 111
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 110
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 110
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 109
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 109
A NEW CYTOGENETIC ABNORMALITY, T(1;4) (P22;P16) IN AML M4 PATIENT AFTER CHEMOTHERAPY TREATMENT 109
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma 109
A GLOBAL PROGRESSION RISK SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: THE NEVER-ENDING STORY 108
Bone turnover markers in patients with type 1 Gaucher disease 108
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 108
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 107
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 107
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 106
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 106
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 106
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 106
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 105
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 105
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 105
Analysis of metabolic parameters coming from basal and interim PET in hodgkin lymphoma 105
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients 105
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 104
Eventi avversi e trigger C12: Stroke in ospedale 104
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia 104
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 103
Acute myeloid leukemia in elderly patients. 100
The Heme Oxygenase System in Hematological Malignancies 100
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 100
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia 99
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 99
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 99
CIRCULATING ARGINASE-1 IN SERUM IS A NOVEL BIO-MARKERIN HODGKIN LYMPHOMA 99
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 99
Multiple Myeloma in 2023 Ways: From Trials to Real Life 98
CD200 EXPRESSION ON MYELOMA CELLS AND ANTITUMOR IMMUNITY 98
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 98
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 98
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 97
Angiogenesis in acute myeloid leukemia 97
A Multicentric clinical trial of salvage therapy with thalidomide for patients with advanced relapsed and refractory multiple myeloma 97
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones? 96
Totale 12.090
Salva come PNG Salva come JPEG
Categoria #
all - tutte 199.599
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 199.599
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.881 0 0 0 0 1.175 67 540 13 470 8 430 178
2021/20225.171 637 763 22 43 872 42 762 175 524 28 122 1.181
2022/20237.429 743 273 104 503 714 1.384 24 1.266 1.976 58 274 110
2023/20243.154 209 432 133 251 142 514 68 206 15 86 676 422
2024/202512.800 99 2.090 837 448 2.795 1.044 380 521 1.091 1.399 960 1.136
2025/202614.884 1.673 1.754 5.013 1.882 4.562 0 0 0 0 0 0 0
Totale 53.800